Who are Effexor's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Effexor, Initial conversion and titration, Remi 0.2.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/venlafaxine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Effexor — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effexor (venlafaxine) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: SNRI (Serotonin-norepinephrine reuptake inhibitor). Area: Neuroscience.

marketed SNRI (Serotonin-norepinephrine reuptake inhibitor) 5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2C Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Effexor (venlafaxine) — Generic (originally Wyeth/Pfizer).

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Effexor TARGET	venlafaxine	Generic (originally Wyeth/Pfizer)	marketed	SNRI (Serotonin-norepinephrine reuptake inhibitor)	5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2C	1993-12-28
Effexor	Effexor	Wyeth is now a wholly owned subsidiary of Pfizer	marketed		5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2C
Initial conversion and titration	Initial conversion and titration	St. Joseph's Hospital and Medical Center, Phoenix	marketed	SNRI (Serotonin-Norepinephrine Reuptake Inhibitor)
Remi 0.2	Remi 0.2	Dokuz Eylul University	marketed	SNRI (Serotonin-Norepinephrine Reuptake Inhibitor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (SNRI (Serotonin-norepinephrine reuptake inhibitor) class)

Generic (originally Wyeth/Pfizer) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Effexor — Competitive Intelligence Brief. https://druglandscape.com/ci/venlafaxine. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing